Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Servier in cardiovascular deal

Servier (Neuilly-sur-Seine, France) granted Amgen Inc. (NASDAQ:AMGN) U.S. commercialization rights to Servier's cardiovascular drug Procoralan ivabradine. The selective

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE